Assistant Professor, Assistant Professor of Molecular Medicine (Mayo Clinic College of Medicine and Science), Assistant Professor of Pathology (University of Arkansas)
Dr. Nagalo was a principal investigator in the following studies:
- cGAS-STING Pathway Targeting Replicative Adenoviruses with CD46 Tropism and AFP Promoter Conditional Replication Restriction for the Treatment of Hepatocellular Carcinoma;
- Virally Induced Alloreactivity for Treatment of Hepatocellular Carcinoma. Development of a gene therapy approach for Treatment of Treatment of Hepatocellular Carcinoma (HCC);
- Hybrid oncolytic VSV for the treatment of pancreatic cancer;
- Generation of a Synthetic Biology-enabled Vesiculovirus to Treat Soft Tissue Sarcoma (sts);
- Hybrid Vesiculovirus Library to Enhance Oncolytic Viral Therapy in Acute Myeloid Leukemia (AML);
- Mayo Clinic Pancreatic Cancer SPORE (co-Investigator) Combination Therapy with Oncolytic Virus and CAR-T in Advanced Pancreatic Cancer;
- Preclinical study of novel oncolytic adenovirus to treat advanced HCC.